4.8 Review

Overcoming Endocrine Resistance in Breast Cancer

Journal

CANCER CELL
Volume 37, Issue 4, Pages 496-513

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2020.03.009

Keywords

-

Funding

  1. UTSW Simmons Cancer Center [P30 CA142543]
  2. CPRIT [RR170061]
  3. NCI Breast SPORE [P50 CA098131]
  4. Susan G. Komen Breast Cancer Foundation [SAC100013]
  5. Breast Cancer Research Foundation
  6. NCI [R01CA224899]

Ask authors/readers for more resources

Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype. Treatment of ER+ breast cancer comprises interventions that suppress estrogen production and/or target the ER directly (overall labeled as endocrine therapy). While endocrine therapy has considerably reduced recurrence and mortality from breast cancer, de novo and acquired resistance to this treatment remains a major challenge. An increasing number of mechanisms of endocrine resistance have been reported, including somatic alterations, epigenetic changes, and changes in the tumor microenvironment. Here, we review recent advances in delineating mechanisms of resistance to endocrine therapies and potential strategies to overcome such resistance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available